دورية أكاديمية
Methamphetamine and the risk of pulmonary arterial hypertension.
| العنوان: | Methamphetamine and the risk of pulmonary arterial hypertension. |
|---|---|
| المؤلفون: | Ramirez RL 3rd; Department of Medicine., Perez VJ; Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine.; Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California., Zamanian RT; Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine.; Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, California. |
| المصدر: | Current opinion in pulmonary medicine [Curr Opin Pulm Med] 2018 Sep; Vol. 24 (5), pp. 416-424. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9503765 Publication Model: Print Cited Medium: Internet ISSN: 1531-6971 (Electronic) Linking ISSN: 10705287 NLM ISO Abbreviation: Curr Opin Pulm Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Philadelphia, PA : Lippincott Williams & Wilkins Original Publication: Philadelphia, PA : Current Science, c1995- |
| مواضيع طبية MeSH: | Amphetamine-Related Disorders/*epidemiology , Hypertension, Pulmonary/*epidemiology , Hypertension, Pulmonary/*etiology , Methamphetamine/*metabolism, Amphetamine-Related Disorders/complications ; Exercise Tolerance ; Humans ; Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/physiopathology ; Inactivation, Metabolic/genetics ; Loss of Function Mutation ; Survival Rate ; Ventricular Dysfunction, Right/etiology |
| مستخلص: | Purpose of Review: Methamphetamine is a highly addictive drug originally developed for the treatment of neuropsychiatric disorders. At present, the epidemic rise of illicit methamphetamine use has increased the number of patients living with medical complications. Our group has recently identified a definite association between methamphetamine use and pulmonary arterial hypertension (PAH), a life-threatening disease characterized by occlusive vasculopathy and progressive right heart failure. This review will discuss the evidence that links methamphetamine with PAH and how to approach the diagnosis and management of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) patients in clinic. Recent Findings: Compared with idiopathic (I) PAH, Meth-APAH patients present with worse functional status, right ventricular dysfunction, and exercise tolerance. Despite therapy, the 5-year survival of Meth-APAH patients is significantly lower compared with IPAH. Genetic studies suggest that loss of function variants in genes involved in drug detoxification can increase susceptibility for methamphetamine-related vascular injury and trigger occlusive vasculopathy. Summary: PAH patients undergoing diagnostic evaluation should be screened for a history of current or past methamphetamine use. Pharmacovigilance should be implemented to monitor patients being treated with methamphetamine for neuropsychiatric disorders (e.g., attention-deficit hyperactivity disorder). More studies will be needed to identify which susceptibility factors increase risk of PAH in methamphetamine users. |
| References: | Eur Respir J. 2014 Dec;44(6):1627-34. (PMID: 25323231) J Pain Palliat Care Pharmacother. 2015 Jun;29(2):102-14. (PMID: 26095479) Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. (PMID: 28934596) Front Psychiatry. 2017 Apr 20;8:61. (PMID: 28473777) Chest. 1993 Aug;104(2):614-6. (PMID: 8101799) Adv Pulm Hypertens. 2017 Jan 1;15(3):133-137. (PMID: 34306297) Am Heart J. 1995 Aug;130(2):398-9. (PMID: 7631626) PLoS One. 2010 Dec 07;5(12):e15269. (PMID: 21151866) Br Med J. 1971 Jan 30;1(5743):265-6. (PMID: 5100497) Am J Addict. 2004 May-Jun;13(3):248-55. (PMID: 15370944) Adv Exp Med Biol. 2010;661:309-22. (PMID: 20204739) Chest. 2006 Dec;130(6):1657-63. (PMID: 17166979) Drug Alcohol Depend. 2014 Jun 1;139:18-25. (PMID: 24685563) CMAJ. 2008 Jun 17;178(13):1679-82. (PMID: 18559805) J Neuroimmune Pharmacol. 2012 Mar;7(1):113-39. (PMID: 21728034) Circulation. 2012 May 1;125(17):2128-37. (PMID: 22451584) JCI Insight. 2017 Jan 26;2(2):e90427. (PMID: 28138562) JACC Heart Fail. 2017 Jun;5(6):435-445. (PMID: 28571597) Chest. 2012 Jun;141(6):1598-1600. (PMID: 22670022) Drug Alcohol Depend. 2018 Apr 1;185:305-312. (PMID: 29486419) Am J Respir Crit Care Med. 2018 Mar 15;197(6):704-706. (PMID: 29043836) Pulm Circ. 2011 Apr;1(2):250-258. (PMID: 22020367) Eur Heart J. 2016 Jan 1;37(1):67-119. (PMID: 26320113) Am J Public Health. 2013 Jul;103(7):1262-70. (PMID: 23078474) West J Med. 1999 Apr;170(4):214-9. (PMID: 10344175) Clin Cardiol. 2013 Dec;36(12):737-42. (PMID: 24037954) Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L967-L983. (PMID: 29417823) Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L252-L266. (PMID: 28473326) Am J Physiol Lung Cell Mol Physiol. 2015 Nov 15;309(10):L1164-73. (PMID: 26386116) Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):77-82. (PMID: 22900600) |
| معلومات مُعتمدة: | R01 HL134776 United States HL NHLBI NIH HHS; R01 HL139664 United States HL NHLBI NIH HHS |
| المشرفين على المادة: | 44RAL3456C (Methamphetamine) |
| تواريخ الأحداث: | Date Created: 20180724 Date Completed: 20190523 Latest Revision: 20231020 |
| رمز التحديث: | 20231020 |
| مُعرف محوري في PubMed: | PMC6880795 |
| DOI: | 10.1097/MCP.0000000000000513 |
| PMID: | 30036313 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1531-6971 |
|---|---|
| DOI: | 10.1097/MCP.0000000000000513 |